Vetirus Pharmaceuticals Unveils Zonexias Hemorapid™
By Angela Grodin-October 6, 2025
In a breakthrough that could save countless lives on operating tables and battlefields alike, Vetirus Pharmaceuticals has unveiled Zonexias Hemorapid™, a groundbreaking hemostatic bioadhesive hailed as the world's first "hydrophobic super glue" for wounds. Drawing inspiration from the potent clotting powers of snake venom, this innovative gel stops severe bleeding in under a minute—far outpacing traditional methods like sutures or fibrin glue—and adhere to tissues even in gushing blood.
The announcement made Monday at a press event from the company's Naples, Florida headquarters, positions Hemorapid™ as a game-changer for emergency medicine, surgery, and trauma care. Developed from pioneering research published in Science Advances in 2021 by Guo et al., the product combines a biocompatible collagen derivative and an enzyme extracted from the venom of the Bothrops atrox snake.
A simple application of visible light (your flashlight on your phone) crosslinks the mixture into a robust, biodegradable seal that not only halts blood loss but also promotes healing.
"Hemorapid™ isn't just an adhesive; it's a paradigm shift in surgical site and wound care," said Robert N. Jordan, CEO of Vetirus Pharmaceuticals. "By harnessing the efficiency of snake venom, we've created a tool that will improve surgical outcomes, allow for repair and closure of currently untreatable conditions, and give medics in the field the edge they need to save lives. This is the future of surgical and trauma care."
Vetirus, a next-generation pharma firm specializing in natural biologics for human and veterinary markets, has rebranded and expanded the technology under its Zonexias line, building on its portfolio of regenerative therapies like Rebound High Performance PRP™. The white paper released alongside the unveiling details Hemorapid™'s stellar performance: In rat models, it achieved hemostasis in just 45 seconds on average—compared to over three minutes for controls—while slashing blood loss by up to 79%. Its adhesive strength? A whopping 93 kPa, about 10 times tougher than fibrin glue, making it ideal for sealing tricky spots like liver incisions or abdominal aorta defects.
What sets Hemorapid™ apart is its "hydrophobic" edge—meaning it repels water (and blood) to form an unbreakable bond in wet environments where other glues wash away. Unlike toxic synthetic options like cyanoacrylates, which can trigger inflammation, or UV-based gels that risk DNA damage, Hemorapid™ uses a gentle visible light system with FDA-approved components like Eosin Y. It's also fully biodegradable, breaking down in about 28 days to support natural tissue regeneration, with minimal inflammation and over 98% cell viability in lab tests.
The potential applications are vast: From speeding up minimally invasive surgeries and periodontal procedures (goodbye, post-extraction stitches!) to battlefield hemorrhage control and chronic wound care for burns or diabetic ulcers. In an era of rising trauma cases—global hemostatic agent markets are booming—analysts see Hemorapid™ capturing a significant slice of the $3 billion-plus industry. Vetirus plans to fast-track regulatory approval, leveraging the product's biocompatible and pre-approved ingredients for a smoother path with the FDA.
Clinical trials in humans are slated to begin next year, with a commercial launch eyed for 2027. As uncontrolled bleeding remains a top killer in accidents and operations, Hemorapid™ arrives at an opportune time. Vetirus invites interested parties to reach out via contact@vetirus.com for more details.
